## **CLAIMS**


What is claimed is:

5 1. Use of a compound in the manufacture of a medicament for the treatment of inflammatory bowel disease, said compound comprising

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is −(CH<sub>2</sub>)<sub>6</sub>-, cis −CH<sub>2</sub>CH=CH-(CH<sub>2</sub>)<sub>3</sub>-, or −CH<sub>2</sub>C≡C-(CH<sub>2</sub>)<sub>3</sub>-, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is −(CH<sub>2</sub>)<sub>m</sub>-Ar-(CH<sub>2</sub>)<sub>0</sub>- wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH<sub>2</sub> may be substituted with S or O; and D is aryl or heteroaryl.

- 15 2. Use of claim 1 wherein D in said compound is phenyl.
  - 3. Use of claim 2 wherein D in said compound is chlorophenyl.
  - 4. Use of claim 3 wherein D in said compound is 3,5-dichlorophenyl.
  - 5. Use of claim 2 wherein D in said compound is unsubstituted phenyl.
  - 6. Use of claim 1 wherein A in said compound is -(CH<sub>2</sub>)<sub>6</sub>-, cis -CH<sub>2</sub>CH=CH-(CH<sub>2</sub>)<sub>3</sub>-, or -CH<sub>2</sub>C≡C-(CH<sub>2</sub>)<sub>3</sub>-.
- 20 7. Use of claim 2, said compound comprising



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R<sup>3</sup> is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH<sub>2</sub>, OH, CN, NO<sub>2</sub>, or CF<sub>3</sub>; and

- 25 n is 0, 1, 2, or 3.
  - 8. Use of claim 7, said compound comprising

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein a dashed line indicates the presence or absence of a covalent bond.

9. Use of claim 2, said compound comprising

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R<sup>3</sup> is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH<sub>2</sub>, OH, CN, NO<sub>2</sub>, or CF<sub>3</sub>;

 $R^4$  is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and n is 0, 1, 2, or 3.

10. A compound comprising

5

10

or a pharmaceutically acceptable salt or a prodrug thereof.

## **AMENDED CLAIMS**

## Received by the International Bureau on 03 October 2006 (03.10.2006)

## What is claimed is:

1. A compound of the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;

A is  $-(CH_2)_6$ -, cis  $-CH_2CH=CH-(CH_2)_3$ -, or  $-CH_2C\equiv C-(CH_2)_3$ -, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is  $-(CH_2)_m$ -Ar- $-(CH_2)_0$ - wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one  $CH_2$  may be substituted with S or O; and D is aryl or heteroaryl.

- 2. The compound of claim 1 wherein D is phenyl.
- 3. The compound of claim 2 wherein D is chlorophenyl.
- 4. The compound of claim 3 wherein D is 3,5-dichlorophenyl.
- 5. The compound of claim 2 wherein D is unsubstituted phenyl.
- 6. The compound according to any one of claims 1 to 5, wherein A is  $-(CH_2)_6$ -, cis  $-CH_2CH=CH-(CH_2)_3$ -, or  $-CH_2C\equiv C-(CH_2)_3$ -.
- 7. The compound of claim 2 having the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R<sup>3</sup> is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH<sub>2</sub>, OH, CN, NO<sub>2</sub>, or CF<sub>3</sub>; and n is 0, 1, 2, or 3.

8. The compound of claim 7 having the formula

WO 2006/121708 PCT/US2006/016804

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein a dashed line indicates the presence or absence of a covalent bond.

9. The compound of claim 2 having the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R<sup>3</sup> is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH<sub>2</sub>, OH, CN, NO<sub>2</sub>, or CF<sub>3</sub>;

 $R^4$  is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and n is 0, 1, 2, or 3.

10. The compound of claim 9 having the formula

or a pharmaceutically acceptable salt or a prodrug thereof.

- 11. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prevention of glaucoma or ocular hypertension.
- 12. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prevention of for the treatment of inflammatory bowel disease.

13. A liquid comprising a compound according to any one of claims 1 to 10, wherein said liquid is ophthalmically acceptable.